Fostemsavir in Treatment-Experienced Patients BRIGHTE Study (Week 48 Data)



Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Background


Study Design: BRIGHTE

Background:

- Phase 3, randomized, multicenter, placebo-controlled, non-inferiority trial evaluating attachment inhibitor fostemsavir (FTR) in salvage ART

Enrollment Criteria:

- Highly ART-experienced adults
- Failing current ART regimen
- HIV RNA >400 copies/mL
- Multiclass ART resistance
- At least one fully active agent
- Unable to construct viable regimen



*Also a cohort with 0 remaining active agents; all given Fostemsavir 600 mg BID + OBR (n = 99) *OBR = optimized background regimen



Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Baseline Characteristics


Baseline Characteristics	Randomized (n = 272)	Non-Randomized (n = 99)
Age, years, median (range)	48 (18-73)	50 (17-72)
Male sex, n (%)	200 (74)	89 (90)
White, n (%)	184 (68)	74 (74)
Black/African American, n (%)	60 (22)	23 (23)
HIV RNA 1,000-100,000 copies/mL, n (%)	161 (59)	75 (76)
HIV RNA >100,000 copies/mL, n (%)	80 (29)	15 (15)
CD4 count—cells/mm ³ , median (range)	99 (0-1160)	41 (0-641)
2 fully active agents in OBR, %	42	0
1 fully active agent in OBR, %	52	19
0 fully active agents in OBR, %	6	81

*Most common ARV's in OBR: dolutegravir, darunavir, tenofovir DF, etravirine, maraviroc, enfuvirtide, ibalizumab



Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Results


Baseline to Day 8 Change in HIV RNA Level





Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Results

Virologic Response Through Week 48 (HIV RNA <40 copies/mL)








Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Results

Adverse Events





Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 48): Conclusion

Conclusion: "In patients with multidrug-resistant HIV-1 infection with limited therapy options, those who received fostemsavir had a significantly greater decrease in the HIV-1 RNA level than those who received placebo during the first 8 days. Efficacy was sustained through 48 weeks."




Fostemsavir in Treatment-Experienced Patients BRIGHTE Study (Week 96 Data)



Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 96): Results


Virologic Response Through Week 96 (HIV RNA <40 copies/mL)





Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 96): Results

Mean Change in CD4 T-Cell Count Through Week 96





Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 96): Results

Adverse Events (AEs)	Randomized (n = 272)	Non-Randomized (n = 99)
Any AE, n (%)	249 (92)	98 (99)
Drug-related grade 2-4 AEs, n (%)	57 (21)	22 (22)
Nausea	9 (3)	5 (5)
Diarrhea	6 (2)	3 (3)
Headache	6 (2)	1 (1)
Vomiting	4 (1)	2 (2)
Fatigue	3 (1)	2 (2)
Asthenia	2 (<1)	2 (2)
Drug-related AE leading to discontinuation, n (%)	7 (3)	7 (3)
Drug-related serious AE, n (%)	9 (3)	3 (30)

Source: Lataillade M, et al. Lancet HIV. 2020;7:e740-51.



Fostemsavir (FTR) for Heavily Treatment Experienced BRIGHTE Study (Week 96): Conclusion

Interpretation: "In heavily treatment-experienced individuals with advanced HIV-1 disease and limited treatment options, fostemsavir-based antiretroviral regimens were generally well tolerated and showed a distinctive trend of increasing virological and immunological response rates through 96 weeks; these findings support fostemsavir as a treatment option for this vulnerable population."

Source: Lataillade M, et al. Lancet HIV. 2020;7(11):e740-51.



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.



